Melamaravakkadu

Maravai LifeSciences To Host Earnings Conference Call on Wednesday, May 8, 2024

Retrieved on: 
Wednesday, April 10, 2024
Melamaravakkadu, Telephone, Conference, Webcast, SAN

SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m.

Key Points: 
  • SAN DIEGO, April 10, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its first quarter 2024 financial and operating results after the market closes on Wednesday, May 8, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m.
  • ET.
  • To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 6629752.
  • The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com .

TriLink BioTechnologies® Announces New San Diego Facility for Late Phase mRNA Drug Substance Production

Retrieved on: 
Thursday, April 18, 2024
Other Health, Research, General Health, Pharmaceutical, Oncology, Infectious Diseases, Clinical Trials, Science, Medical Supplies, FDA, Other Science, Health, Safety, Cancer, Gene editing, NTP, Vaccine, CDMO, Melamaravakkadu, SaRNA, Biotechnology, Infection, Multimedia, Messenger, GMP, COVID-19, CGMP

TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility .

Key Points: 
  • TriLink BioTechnologies (TriLink®), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has announced the grand opening of its new cGMP mRNA manufacturing facility .
  • The 32,000-square-foot facility was specifically designed for mRNA manufacturing to support late-phase drug developers from Phase 2 to commercialization via TriLink’s robust mRNA manufacturing capabilities .
  • View the full release here: https://www.businesswire.com/news/home/20240418722567/en/
    TriLink BioTechnologies® Cuts Ribbon on New San Diego Facility for Late Phase mRNA Drug Substance Production (Photo: TriLink BioTechnologies®)
    Located in the Sorrento Valley area of San Diego, the facility features individual Grade C cleanroom suites for mRNA manufacturing, increased mRNA capacity (1g to >100g per batch), comprehensive in-house analytical services, and laboratory space for on-site quality control testing.
  • TriLink has reliably delivered GMP services to drug developers since the debut of its first cGMP facility in 2015.

Dyadic Reports 2023 Full Year Results and Recent Company Progress

Retrieved on: 
Thursday, March 28, 2024
Cygnus, Enzyme, Rabies, SAHPRA, Biology, Sale, Innovation, Infection, Note, European, AVATAR, Therapy, Host cell protein, Vaccine, Analysis, Convertible, Research, Biotechnology, A-DNA, Massachusetts General Hospital, Partnership, Melamaravakkadu, Webcast, Primate, RNA, Biofuel, C1, Virology, SME, Safety, Nature Communications, Transferrin, Livestock, Global health, Manuscript, Food, Senior, NIIMBL, Antibody, Hospital, Antigen, Diagnosis, Health, Pithing, RBD, Phibro Animal Health, COVID-19, Dyadic, Messenger, Protein, Human

“In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.

Key Points: 
  • “In 2023, Dyadic achieved significant milestones in unlocking the potential of its microbial platforms.
  • We believe that we are well-positioned, both financially and scientifically, to execute our strategic plan with enhanced capabilities and resources.
  • For the year ended December 31, 2023, the Company received a total of approximately $1.3 million in connection with the sale of Alphazyme LLC.
  • Other Income: For the year ended December 31, 2023, the Company had a gain of approximately $1,018,000 from the sale of the Company’s equity interest in Alphazyme, LLC.

Maravai LifeSciences Announces March 2024 Investor Conference Schedule

Retrieved on: 
Tuesday, March 12, 2024
PDT, Melamaravakkadu, Webcast, Medtech, SAN, News

SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of March.

Key Points: 
  • SAN DIEGO, March 12, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conference during the month of March.
  • On March 19, 2024, at 11:15 a.m. PDT, Trey Martin, Chief Executive Officer will participate in a fireside chat at the KeyBanc Capital Markets Life Sciences and MedTech Investor Forum being held virtually.
  • A live webcast of the presentation will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events , Upcoming events .
  • An archived version of the webcast will also be available on the Maravai website after the event is completed.

TriLink BioTechnologies® Solidifies IP Position with Awarded Patents for CleanCap® Capping Technology in China and Canada

Retrieved on: 
Wednesday, February 21, 2024
Research, Infectious Diseases, FDA, Genetics, Other Health, Biotechnology, Pharmaceutical, Health, Science, Other Science, Maker, Therapy, Messenger, CIPO, Vaccine, General counsel, ARCA, COVID-19, SaRNA, CNIPA, Intellectual property, Melamaravakkadu, Human

“mRNA technology continues to prove its value as a breakthrough modality for innovative medicines,” explained Drew Burch, President of Nucleic Acid Production at TriLink.

Key Points: 
  • “mRNA technology continues to prove its value as a breakthrough modality for innovative medicines,” explained Drew Burch, President of Nucleic Acid Production at TriLink.
  • CleanCap® technology has been used in commercially approved COVID-19 mRNA and saRNA vaccines.
  • “TriLink’s CleanCap technology is helping to bring life-saving therapeutics and vaccines to market faster,” added Kurt Oreshack, Executive Vice President & General Counsel, Maravai LifeSciences.
  • “These additional jurisdictions fortify the validity and strength of our global intellectual property.”
    Last May, TriLink launched its most robust analog to date: CleanCap® M6 .

Dyadic and Cygnus Technologies Announce Partnership To Provide C1 HCP ELISA Assay to Enhance Quality Assurance in Biomanufacturing

Retrieved on: 
Tuesday, February 13, 2024
HCP, Antigen, Patient, Melamaravakkadu, Partnership

Under the terms of the partnership agreement, Cygnus has developed the C1 HCP ELISA Kit, which will be made available to Dyadic and Cygnus customers.

Key Points: 
  • Under the terms of the partnership agreement, Cygnus has developed the C1 HCP ELISA Kit, which will be made available to Dyadic and Cygnus customers.
  • The development of the C1 HCP ELISA Kit further demonstrates that Dyadic’s C1 protein expression platform is keeping pace with industry standards for HCP analysis in biopharmaceutical manufacturing.
  • Mark Emalfarb, CEO of Dyadic, commented, “I can’t stress enough the significance of our partnership with Cygnus, the C1 HCP assay provides adopters of our C1 microbial production platform a solution for testing C1 HCP impurity during product lot release testing, thereby enhancing the quality assurance process in biomanufacturing.
  • Our collaboration with Cygnus resulted in the development of a first-in-class C1 HCP ELISA assay, making a significant step toward greater adoption of the C1 technology globally.”
    Christine Dolan, Cygnus Technologies Chief Operating Officer, stated, “We are very excited about the launch of the highly anticipated C1 HCP ELISA Assay.

Maravai LifeSciences To Host Earnings Conference Call on Thursday, February 22, 2024

Retrieved on: 
Monday, January 29, 2024
SAN, Telephone, Melamaravakkadu, Conference, Webcast

SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, February 22, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m.

Key Points: 
  • SAN DIEGO, Jan. 29, 2024 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its fourth quarter and full year 2023 financial and operating results after the market closes on Thursday, February 22, 2024, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m.
  • ET.
  • To participate in the conference call by telephone, dial (888) 596-4144 or (646) 968-2525 and reference Maravai LifeSciences, Conference ID 4939675.
  • The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com .

Maravai LifeSciences Announces November 2023 Investor Conference Schedule

Retrieved on: 
Thursday, November 9, 2023
Lotte New York Palace Hotel, The Waldorf Hilton, London, EST, Conference, News, Baozou Big News Events, Melamaravakkadu, CFO, SAN, Management

SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.

Key Points: 
  • SAN DIEGO, Nov. 09, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, is scheduled to participate in the following investor conferences during the month of November.
  • On November 14, 2023, at 10:55 a.m. EST, Trey Martin, Chief Executive Officer (CEO) and Kevin Herde, Chief Financial Officer (CFO), will participate in a fireside chat at the Stifel Healthcare Conference, 2023, being held at the Lotte New York Palace Hotel, in New York City, NY.
  • A live webcast of the presentations will be available to all interested parties on the Maravai LifeSciences Investor Relations website, under News & Events .
  • An archived version of the webcasts will also be available on the Maravai website following the completion of each event.

TriLink BioTechnologies® Expands Capabilities with Launch of ‘Analytical Sciences Center of Excellence’

Retrieved on: 
Thursday, November 2, 2023
FDA, Health, Infectious Diseases, Research, Science, Biotechnology, Laboratory, Dicarboxylic acid, NMR, Therapy, Vaccine, CDMO, ASCE, DNA, Growth, NGS, Melamaravakkadu, Messenger, LNP, Education, Communities and Justice Directorates, GM, Quality control, Fine chemical

TriLink BioTechnologies ® (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its Analytical Sciences Center of Excellence (ASCE) hub.

Key Points: 
  • TriLink BioTechnologies ® (TriLink), a Maravai LifeSciences company (NASDAQ: MRVI) and global provider of life science reagents and services, has launched its Analytical Sciences Center of Excellence (ASCE) hub.
  • Expanding its comprehensive suite of analytical testing capabilities, this new center of excellence will minimize the delays and unexpected costs typically associated with outsourced testing to multiple laboratories.
  • This new center of excellence will serve as the hub for all analytical innovation and the Quality Control laboratories across the organization’s manufacturing network.
  • “TriLink's new Analytical Sciences Center of Excellence will be a transformative force in the development of nucleic acid therapies,” shared Khaled Yamout, Senior Director of Analytical Services at TriLink.

Maravai LifeSciences To Host Earnings Conference Call on Tuesday, November 7, 2023

Retrieved on: 
Tuesday, October 17, 2023
Webcast, Telephone, Conference, Melamaravakkadu, SAN, Communications satellite, Internet service provider, Mobile phone

SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2023 financial and operating results after the market closes on Tuesday, November 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m.

Key Points: 
  • SAN DIEGO, Oct. 17, 2023 (GLOBE NEWSWIRE) -- Maravai LifeSciences, Inc. (Maravai) (NASDAQ: MRVI), a global provider of life science reagents and services to researchers and biotech innovators, plans to announce its third quarter 2023 financial and operating results after the market closes on Tuesday, November 7, 2023, and will host a conference call and webcast on the same day at 2:00 p.m. PT/ 5:00 p.m.
  • ET.
  • To participate in the conference call by telephone, dial (800) 715-9871 or (646) 307-1963 and reference Maravai LifeSciences, Conference ID 4621071.
  • The call will also be available via live or archived webcast on the "Investors" section of the Maravai web site at https://investors.maravai.com .